application's abstract): The Adult AIDS Clinical Trials Group (AACTG) is a multicenter, multidisciplinary clinical trials group dedicated to the study of HIV pathogenesis and therapy. Since its inception in 1987, the AACTG has evolved into a cooperative group consisting of the Central Group (composed of the Office of the Group Chair, Executive, Scientific and Resource Committee, a state-of-the-art laboratory network, a Community Constituency Group, and the Operations Center), 30 AIDS Clinical Trials Units (ACTUs) located at major academic medical centers, and the Statistical and Data Management Center. The AACTG has had an impact on elucidating the current understanding of AIDS pathogenesis and therapy, and has played a role in the development of novel trial designs and analysis strategies. AACTG clinical trials have helped define guidelines for the use of antiretroviral agents and for the prophylaxis and treatment of HIV- associated opportunistic complications. Over 200 manuscripts have been published by the AACTG describing this body of work since submission of the prior competing renewal application in 1995. Group productivity has been aided by collaborations with a wide variety of external investigators and laboratories, U.S. and international clinical trials networks, and members of the pharmaceutical and medical diagnostics industries. The AACTG proposes to build on its accomplishments with the goal of further reducing, and ultimately eliminating, HIV-associated morbidity and mortality. The applicants propose to undertake investigations in a structure that allows for a high degree of efficiency and flexibility in the design and implementation of a broad array of clinical trials with patient management principles, according to the applicant, which are reflective of contemporary clinical practice and designed to ensure the relevance of research findings. Over the next several years the Group proposes to address a number of issues including how best to: provide initial and subsequent treatment to maximally suppress HIV replication; provide optimum treatment strategies following treatment failure; develop approaches to individualization of therapy based on genotypic and phenotypic characteristics of the virus and/or host; eliminate reservoirs of HIV-1 in latently infected cells; ameliorate virologic, immunologic, pharmacologic, and behavioral factors (adherence) that contribute to treatment failure; incorporate new therapies and treatment strategies into future regimens; evaluate new strategies for enhancing immune reconstitution to HIV and OIs; and delay or prevent HIV disease progression, opportunistic complications, complications of therapy, and mortality. To accomplish this agenda, the Group requests funds for 35 ACTUs that are to be evaluated on objective performance criteria. New sites and laboratories have been added to the Group in order to provide additional expertise in virology, immunology, and pharmacology. The Group remains committed to enrolling women and minorities and to continuing support of the Minority AIDS Training Program.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01AI038858-05
Application #
6021494
Study Section
Special Emphasis Panel (ZAI1-PSS-A (S1))
Program Officer
Batzold, Frederick
Project Start
1996-01-01
Project End
2004-12-31
Budget Start
2000-01-01
Budget End
2000-12-31
Support Year
5
Fiscal Year
2000
Total Cost
$17,606,010
Indirect Cost
Name
Social and Scientific Systems, Inc.
Department
Type
DUNS #
City
Silver Spring
State
MD
Country
United States
Zip Code
20910
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Stein, James H; Yeh, Eunice; Weber, Joanne M et al. (2018) Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate. Arterioscler Thromb Vasc Biol 38:2870-2878
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Kelesidis, Theodoros; Moser, Carlee B; Johnston, Elizabeth et al. (2018) Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s. J Acquir Immune Defic Syndr 78:362-366
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Stekler, Joanne D; Milne, Ross; Payant, Rachel et al. (2018) Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort. PLoS Med 15:e1002537
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Jennings, Cheryl; Wager, Carrie G; Scianna, Salvatore R et al. (2018) Use of External Quality Control Material for HIV-1 RNA Testing To Assess the Comparability of Data Generated in Separate Laboratories and the Stability of HIV-1 RNA in Samples after Prolonged Storage. J Clin Microbiol 56:

Showing the most recent 10 out of 648 publications